首页> 外文期刊>Expert opinion on therapeutic targets >EGFL7 - a potential therapeutic target for multiple sclerosis?
【24h】

EGFL7 - a potential therapeutic target for multiple sclerosis?

机译:EGFL7 - 多发性硬化症的潜在治疗靶标?

获取原文
获取原文并翻译 | 示例
           

摘要

Multiple sclerosis (MS) is a leading cause of disability in young adults. MS is characterized by demyelinating lesions of the central nervous system (CNS), initiated by the infiltration of pro-inflammatory peripheral immune cells across a dysfunctional blood-brain barrier (BBB), that are disseminated in time and space. The perivascular infiltration of pro-inflammatory immune cells through a compromised BBB is considered an early phenomenon in MS pathology. Potent disease-modifying therapies for MS are rapidly emerging, but most therapies are immunosuppressive, targeting the peripheral immune cell compartment to control neuroinflam-mation. To date, only one agent, natalizumab, directly targets transmigration to the CNS by blocking a surface molecule used by leukocytes to interact with BBB endothelial cells. Novel alternative treatment strategies promoting the barrier function of the BBB are needed to protect the CNS from aberrantly activated immune cells in MS without causing CNS immunosuppression.
机译:多发性硬化症(MS)是年轻成年人残疾的主要原因。 MS的特征在于在中枢神经系统(CNS)的脱髓鞘中,通过在功能障碍血脑屏障(BBB)上的促炎外周血免疫细胞的浸润引发,所述血脑屏障(BBB)在时间和空间中散发。通过受损的BBB的促炎症免疫细胞的血管渗透被认为是MS病理学的早期现象。用于MS的有效的疾病修饰疗法是迅速的,但大多数疗法是免疫抑制作用,靶向外周免疫细胞室以控制神经胰腺炎。迄今为止,只有一个代理商Natalizumab通过阻断白细胞使用的表面分子直接针对CNS迁移,以与BBB内皮细胞相互作用。需要新的替代治疗策略,促进BBB屏障功能,以保护CNS在MS中的异常活化的免疫细胞,而不会导致CNS免疫抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号